Li Lijuan, Wang Dong, Pan Hongxia, Huang Liyi, Sun Xin, He Chengqi, Wei Quan
Rehabilitation Medicine Center and Institute of Rehabilitation Medicine, West China Hospital, Sichuan University, Chengdu, China.
Key Laboratory of Rehabilitation Medicine in Sichuan Province, Sichuan University, Chengdu, China.
Front Neurosci. 2022 Feb 16;16:820665. doi: 10.3389/fnins.2022.820665. eCollection 2022.
Stroke poses a serious threat to human health and burdens both society and the healthcare system. Standard rehabilitative therapies may not be effective in improving functions after stroke, so alternative strategies are needed. The FDA has approved vagus nerve stimulation (VNS) for the treatment of epilepsy, migraines, and depression. Recent studies have demonstrated that VNS can facilitate the benefits of rehabilitation interventions. VNS coupled with upper limb rehabilitation enhances the recovery of upper limb function in patients with chronic stroke. However, its invasive nature limits its clinical application. Researchers have developed a non-invasive method to stimulate the vagus nerve (non-invasive vagus nerve stimulation, nVNS). It has been suggested that nVNS coupled with rehabilitation could be a promising alternative for improving muscle function in chronic stroke patients. In this article, we review the current researches in preclinical and clinical studies as well as the potential applications of nVNS in stroke. We summarize the parameters, advantages, potential mechanisms, and adverse effects of current nVNS applications, as well as the future challenges and directions for nVNS in cerebral stroke treatment. These studies indicate that nVNS has promising efficacy in reducing stroke volume and attenuating neurological deficits in ischemic stroke models. While more basic and clinical research is required to fully understand its mechanisms of efficacy, especially Phase III trials with a large number of patients, these data suggest that nVNS can be applied easily not only as a possible secondary prophylactic treatment in chronic cerebral stroke, but also as a promising adjunctive treatment in acute cerebral stroke in the near future.
中风对人类健康构成严重威胁,并给社会和医疗系统带来负担。标准的康复治疗可能对改善中风后的功能无效,因此需要替代策略。美国食品药品监督管理局(FDA)已批准迷走神经刺激(VNS)用于治疗癫痫、偏头痛和抑郁症。最近的研究表明,VNS可以促进康复干预的效果。VNS联合上肢康复可增强慢性中风患者上肢功能的恢复。然而,其侵入性限制了其临床应用。研究人员开发了一种非侵入性方法来刺激迷走神经(非侵入性迷走神经刺激,nVNS)。有人提出,nVNS联合康复可能是改善慢性中风患者肌肉功能的一种有前景的替代方法。在本文中,我们综述了nVNS在中风方面的临床前和临床研究现状以及潜在应用。我们总结了当前nVNS应用的参数、优点、潜在机制和不良反应,以及nVNS在脑卒治疗中的未来挑战和方向。这些研究表明,nVNS在减少缺血性中风模型的中风体积和减轻神经功能缺损方面具有有前景的疗效。虽然需要更多的基础和临床研究来充分了解其疗效机制,特别是需要大量患者参与的III期试验,但这些数据表明,nVNS不仅可以作为慢性脑卒可能的二级预防性治疗轻松应用,而且在不久的将来还可以作为急性脑卒一种有前景的辅助治疗方法。